Skip to content

Released Nov 12, 2024, before the open

10-Q filed Nov 12, 2024, 43 days after period end · 0002023658-24-000002

Q3 2024 · 10-Q
Revenue—
Net Income-$17.48MN/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$1.60N/M vs Q3 2023N/M vs Q2 2024
Operating Income-$20,628,000N/M
Operating Cash Flowderived-$17,224,000—
Free Cash Flowderived-$17,232,000—

What the release said

The release

Same quarter

MetricQ3 2024Q3 2023
Net Income-$17.48M-$22.85M
EPS Diluted-$1.60-$38.23

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Bicara Therapeutics Inc. · CIK 2023658 · Engraved from SEC EDGAR